This article is more than 5 years old. Information may no longer be current.

Alcon reports sales increase of 12.4% in third quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HUNENBERG, Switzerland — Global sales for Alcon Inc. increased to $1.2 billion in the third quarter of 2006, a 12.4% increase over the third quarter of 2005, the company announced.

Alcon reported net earnings for the quarter of $232.1 million, or $0.76 per diluted share, compared to $295.8 million, or $0.95 per share, for the third quarter of 2005.

Pharmaceutical sales grew 13.5% to $496.7 million, largely due to increased sales of the glaucoma medications Travatan (travoprost) and Azopt (brinzolamide).

Surgical sales grew 9.2% to $528.7 million. IOL sales increased 13.6% to $191.8 million, with AcrySof IOL sales increasing 11.3%. Refractive revenue increased 4.3%, despite a $92 million non-cash "impairment charge related to some aspects of the ... refractive laser business," company officials said in a press release.

Consumer eye care sales increased 19.7% to $178.4 million. Sales of contact lens disinfectants grew 28.7%, and sales of artificial tears increased 21.3%, primarily due to increased sales of Systane lubricant eye drops.

Alcon currently expects total sales for the full year 2006 to be between $4.87 and $4.9 billion, according to the release.